===
EQS-News: Defence Therapeutics Inc. / Key word(s): Study
DEFENCE'S ARM-X ANTI-CANCER VACCINE INHIBITS GROWTH OF PRE-ESTABLISHED OVARIAN CANCER RESULTING IN COMPLETE RESPONSES
IN TREATED ANIMALS
2024-06-25 / 08:00 CET/CEST

The issuer is solely responsible for the content of this announcement.  
CSE: DTC  FSE: DTC  USOTC: DTCFF       PRESS RELEASE 

Vancouver, BC, Canada, June 25th, 2024 - Defence Therapeutics Inc. ("Defence" or the "Company"), a Canadian
biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to
announce that its second-generation ARM-X anti-cancer vaccine is therapeutically effective against pre-established
ovarian cancer (ID8 model) when combined with the anti-PD-1 immune-checkpoint inhibitor.

Using Defence's Accum® platform, the Company previously demonstrated that AccuTOX® treatment of MSCs results in the
induction of antigen cross-presentation capacity (ARM-X cells), which can mount potent anti-tumoral responses in animal
pre-clinical models. This was previously achieved using various cancer models including solid T-cell lymphoma, melanoma
and pancreatic cancer. Defence just completed an additional study where animals with pre-established ovarian cancer
responded to a combination therapy including ARM-X and anti-PD-1. The latter group prolonged animal survival beyond 80
days post-vaccination, and it led to a complete response in almost all treated animals as shown in Figure 1.

"This is the 4^th cancer model that we efficiently targeted using our ARM-X antic-cancer vaccine. The purpose of
testing our vaccine in various models is to highlight how ARM-X can be adapted to the needs of any patient, no matter
the type of cancer, given that we have access to a tumor biopsy." says Mr. Sebastien Plouffe, Chief Executive Officer
of Defence Therapeutics.
One of the major advantages of Defence's ARM-X vaccine is the need of lower antigen amounts to manufacture the vaccine.
This is important as it avoids the need of a big tumor sample in the vaccine generation. Defence is currently testing
its ARM-X vaccine on colon as an additional indication. These results will set the target indication for the Phase
I-IIa trials, and it also shows how versatile and adaptable can the ARM-X anti-cancer vaccine be.

About Defence:
Defence Therapeutics is a publicly-traded clinical-stage biotechnology company working on engineering the next
generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the
ACCUM® technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells.
As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious
diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
https://www.linkedin.com/company/defence-therapeutics

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this
release, other than statements of historical facts, that address events or developments that the Company expects to
occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are
generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends",
"estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may",
"could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements
are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may
differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ
materially from those in forward-looking statements include regulatory actions, market prices, and continued
availability of capital and financing, and general economic, market or business conditions. Investors are cautioned
that any such statements are not guarantees of future performance and actual results or developments may differ
materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs,
estimates and opinions of the Company's management on the date the statements are made. Except as required by
applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the
event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility
for the adequacy or accuracy of this release.


2024-06-25 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com  
Language:     English 
Company:      Defence Therapeutics Inc. 

1680 - 200 Burrard St
V6C3L6 Vancouver
Canada

E-mail:       info@defencetherapeutics.com 
Internet:     https://defencetherapeutics.com 
ISIN:         CA24463V1013 
WKN:          A3CN14 
Listed:       Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto 
EQS News ID:  1931953 

End of News EQS News Service
===
1931953 2024-06-25 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1931953&application_name=news

END) Dow Jones Newswires

June 25, 2024 02:00 ET (06:00 GMT)